These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27211267)

  • 1. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.
    Mitton B; Chae HD; Hsu K; Dutta R; Aldana-Masangkay G; Ferrari R; Davis K; Tiu BC; Kaul A; Lacayo N; Dahl G; Xie F; Li BX; Breese MR; Landaw EM; Nolan G; Pellegrini M; Romanov S; Xiao X; Sakamoto KM
    Leukemia; 2016 Dec; 30(12):2302-2311. PubMed ID: 27211267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway.
    Chae HD; Cox N; Capolicchio S; Lee JW; Horikoshi N; Kam S; Ng AA; Edwards J; Butler TL; Chan J; Lee Y; Potter G; Capece MC; Liu CW; Wakatsuki S; Smith M; Sakamoto KM
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2307-2315. PubMed ID: 31253529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters.
    Mitton B; Hsu K; Dutta R; Tiu BC; Cox N; McLure KG; Chae HD; Smith M; Eklund EA; Solow-Cordero DE; Sakamoto KM
    Oncotarget; 2016 Feb; 7(8):8653-62. PubMed ID: 26840025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways.
    Chae HD; Cox N; Dahl GV; Lacayo NJ; Davis KL; Capolicchio S; Smith M; Sakamoto KM
    Oncotarget; 2018 Jan; 9(4):4301-4317. PubMed ID: 29435104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
    Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
    J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress.
    Lee JW; Park HS; Park SA; Ryu SH; Meng W; Jürgensmeier JM; Kurie JM; Hong WK; Boyer JL; Herbst RS; Koo JS
    PLoS One; 2015; 10(4):e0122628. PubMed ID: 25897662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis.
    Jiang M; Yan Y; Yang K; Liu Z; Qi J; Zhou H; Qian N; Zhou Q; Wang T; Xu X; Xiao X; Deng L
    J Cell Mol Med; 2019 Feb; 23(2):1224-1234. PubMed ID: 30461194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.
    Giotopoulos G; Chan WI; Horton SJ; Ruau D; Gallipoli P; Fowler A; Crawley C; Papaemmanuil E; Campbell PJ; Göttgens B; Van Deursen JM; Cole PA; Huntly BJ
    Oncogene; 2016 Jan; 35(3):279-89. PubMed ID: 25893291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICER evokes Dusp1-p38 pathway enhancing chemotherapy sensitivity in myeloid leukemia.
    Pigazzi M; Manara E; Beghin A; Baron E; Tregnago C; Basso G
    Clin Cancer Res; 2011 Feb; 17(4):742-52. PubMed ID: 21325296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of CREB as a prognostic marker in acute myeloid leukemia.
    Cheng JC; Esparza S; Sandoval S; Shankar D; Fu C; Sakamoto KM
    Future Oncol; 2007 Aug; 3(4):475-80. PubMed ID: 17661722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of CREB knockdown in myeloid leukemia cells.
    Pellegrini M; Cheng JC; Voutila J; Judelson D; Taylor J; Nelson SF; Sakamoto KM
    BMC Cancer; 2008 Sep; 8():264. PubMed ID: 18801183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
    Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
    J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells.
    Du Y; Li K; Wang X; Kaushik AC; Junaid M; Wei D
    FEBS J; 2020 Apr; 287(8):1645-1665. PubMed ID: 31625692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cyclic AMP response element binding protein in human leukemias.
    Shankar DB; Cheng JC; Sakamoto KM
    Cancer; 2005 Nov; 104(9):1819-24. PubMed ID: 16196046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
    J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
    Wang J; Yang ZH; Chen H; Li HH; Chen LY; Zhu Z; Zou Y; Ding CC; Yang J; He ZW
    BMC Cancer; 2016 Mar; 16():257. PubMed ID: 27036119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
    Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW
    Cell Stem Cell; 2014 Dec; 15(6):775-90. PubMed ID: 25479751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.